Literature DB >> 10934646

Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts.

S Takeshita1, K Kaji, A Kudo.   

Abstract

Osteoclasts are thought to belong to a macrophage lineage. However, the nature of common precursors of osteoclasts and macrophages remains to be investigated. We have characterized the differentiation potential of mouse bone marrow macrophages into mature osteoclasts. Monocyte macrophage-colony-stimulating factor (M-CSF) stimulated the proliferation of bone marrow macrophages in a dose-dependent manner and these M-CSF-dependent bone marrow macrophage (MDBM) cells efficiently differentiated into the tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts in the presence of soluble RANKL (sRANKL) and M-CSF in the in vitro culture. The macrophage-like cell line TMC16 was established from tsA58 (temperature-sensitive SV40 large T-antigen) transgenic mice in the same manner to the preparation of MDBM cells and also differentiated into mature osteoclasts. During this differentiation in vitro, the morphology of the cells changed from spindle to round and smaller (termed pOC) on day 2 and to multinuclear (termed multinucleated cells [MNCs]) on day 4. The surface expression of macrophage marker CD14 was down-regulated and that of CD43 was up-regulated on pOC, analyzed by flow cytometry. RNA analysis revealed that osteoclast marker genes such as calcitonin receptor (CTR), carbonic anhydrase II (CAII), cathepsin K (cath K), MMP9, and TRAP were strongly expressed in MNCs and weakly in pOC whereas MDBM cells did not express these genes. However, the osteopontin (OPN) gene was strongly expressed in MDBM cells and this expression became weakened after differentiation into pOC. The TMC16 cell line weakly expressed cath K, TRAP, and OPN, suggesting that the TMC16 cell line is immortalized at a stage slightly differentiated from MDBM cells. Furthermore, cell sorting analysis revealed that osteoclast early progenitors in bone marrow cells are preferentially present in the Mac-1- F4/80dull population, which differentiated into MDBM cells (the osteoclast progenitor) expressing Mac-1+ F4/80int, suggesting that M-CSF plays roles of a differentiation factor as well as a growth factor for osteoclast early progenitors. These results showed the transition of morphology, surface markers, and gene expression from the early to mature stage in osteoclast differentiation. We propose three differentiation stages in the osteoclast lineage: the pro-osteoclast (spindle-shaped macrophage cells), the pre-osteoclast (small round mononucleated TRAP-positive cells), and the mature osteoclast (multinucleated TRAP-positive cells) stage.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10934646     DOI: 10.1359/jbmr.2000.15.8.1477

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  229 in total

Review 1.  Acid phosphatases.

Authors:  H Bull; P G Murray; D Thomas; A M Fraser; P N Nelson
Journal:  Mol Pathol       Date:  2002-04

2.  Molecular mechanisms of the biphasic effects of interferon-γ on osteoclastogenesis.

Authors:  Jing Cheng; Jianzhong Liu; Zhenqi Shi; Joel Jules; Duorong Xu; Shaokai Luo; Shi Wei; Xu Feng
Journal:  J Interferon Cytokine Res       Date:  2011-12-05       Impact factor: 2.607

3.  Development of a chimaeric receptor approach to study signalling by tumour necrosis factor receptor family members.

Authors:  Duorong Xu; Zhenqi Shi; Jay McDonald; George Pan; Xuemei Cao; Xueqing Yu; Xu Feng
Journal:  Biochem J       Date:  2004-10-15       Impact factor: 3.857

4.  Microfibril-associated glycoprotein-1, an extracellular matrix regulator of bone remodeling.

Authors:  Clarissa S Craft; Wei Zou; Marcus Watkins; Susan Grimston; Michael D Brodt; Thomas J Broekelmann; Justin S Weinbaum; Steven L Teitelbaum; Richard A Pierce; Roberto Civitelli; Matthew J Silva; Robert P Mecham
Journal:  J Biol Chem       Date:  2010-05-25       Impact factor: 5.157

5.  Cdc42 regulates bone modeling and remodeling in mice by modulating RANKL/M-CSF signaling and osteoclast polarization.

Authors:  Yuji Ito; Steven L Teitelbaum; Wei Zou; Yi Zheng; James F Johnson; Jean Chappel; F Patrick Ross; Haibo Zhao
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

6.  Distinct roles of adenylyl cyclase VII in regulating the immune responses in mice.

Authors:  Biyan Duan; Richard Davis; Eva L Sadat; Julie Collins; Paul C Sternweis; Dorothy Yuan; Lily I Jiang
Journal:  J Immunol       Date:  2010-05-26       Impact factor: 5.422

7.  Lack of CD47 impairs bone cell differentiation and results in an osteopenic phenotype in vivo due to impaired signal regulatory protein α (SIRPα) signaling.

Authors:  Cecilia Koskinen; Emelie Persson; Paul Baldock; Åsa Stenberg; Ingrid Boström; Takashi Matozaki; Per-Arne Oldenborg; Pernilla Lundberg
Journal:  J Biol Chem       Date:  2013-08-29       Impact factor: 5.157

8.  Steap4 plays a critical role in osteoclastogenesis in vitro by regulating cellular iron/reactive oxygen species (ROS) levels and cAMP response element-binding protein (CREB) activation.

Authors:  Jian Zhou; Shiqiao Ye; Toshifumi Fujiwara; Stavros C Manolagas; Haibo Zhao
Journal:  J Biol Chem       Date:  2013-08-29       Impact factor: 5.157

9.  Deletion of ferroportin in murine myeloid cells increases iron accumulation and stimulates osteoclastogenesis in vitro and in vivo.

Authors:  Lei Wang; Bin Fang; Toshifumi Fujiwara; Kimberly Krager; Akshita Gorantla; Chaoyuan Li; Jian Q Feng; Michael L Jennings; Jian Zhou; Nukhet Aykin-Burns; Haibo Zhao
Journal:  J Biol Chem       Date:  2018-05-03       Impact factor: 5.157

10.  GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer.

Authors:  Anna-Karin M Sjogren; Karin M E Andersson; Meng Liu; Briony A Cutts; Christin Karlsson; Annika M Wahlstrom; Martin Dalin; Carolyn Weinbaum; Patrick J Casey; Andrej Tarkowski; Birgitta Swolin; Stephen G Young; Martin O Bergo
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.